Sellas Life Sciences Group is a late-stage immuno-oncology company developing peptide-based cancer vaccines and targeted small molecules. Its lead programme, galinpepimut-S, targets the WT1 antigen in acute myeloid leukemia and other WT1-expressing cancers.
Sellas Life Sciences’ investigational cancer vaccine prolonged median overall survival by over nine months compared to standard of care in a Phase 3 trial for difficult-to-treat acute myeloid leukemia.